Literature DB >> 32611614

The Gut Microbiota Impact Cancer Etiology through "Phase IV Metabolism" of Xenobiotics and Endobiotics.

Samantha M Ervin1, Matthew R Redinbo2,3.   

Abstract

The human gut microbiome intimately complements the human genome and gut microbial factors directly influence health and disease. Here we outline how the gut microbiota uniquely contributes to cancer etiology by processing products of human drug and endobiotic metabolism. We formally propose that the reactions performed by the gut microbiota should be classified as "Phase IV xenobiotic and endobiotic metabolism." Finally, we discuss new data on the control of cancer by the inhibition of gut microbial phase IV enzymes responsible for tumor initiation and progression. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32611614     DOI: 10.1158/1940-6207.CAPR-20-0155

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  3 in total

1.  β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics.

Authors:  Francesco Candeliere; Stefano Raimondi; Raffaella Ranieri; Eliana Musmeci; Alfonso Zambon; Alberto Amaretti; Maddalena Rossi
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

2.  Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate.

Authors:  Joshua B Simpson; Josh J Sekela; Amanda L Graboski; Valentina B Borlandelli; Marissa M Bivins; Natalie K Barker; Alicia A Sorgen; Angie L Mordant; Rebecca L Johnson; Aadra P Bhatt; Anthony A Fodor; Laura E Herring; Hermen Overkleeft; John R Lee; Matthew R Redinbo
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 3.  Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.

Authors:  Mora Guardamagna; Miguel-Angel Berciano-Guerrero; Beatriz Villaescusa-González; Elisabeth Perez-Ruiz; Javier Oliver; Rocío Lavado-Valenzuela; Antonio Rueda-Dominguez; Isabel Barragán; María Isabel Queipo-Ortuño
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.